CN102574807A - 螺哌啶化合物及其用于治疗糖尿病的药用 - Google Patents

螺哌啶化合物及其用于治疗糖尿病的药用 Download PDF

Info

Publication number
CN102574807A
CN102574807A CN2010800462763A CN201080046276A CN102574807A CN 102574807 A CN102574807 A CN 102574807A CN 2010800462763 A CN2010800462763 A CN 2010800462763A CN 201080046276 A CN201080046276 A CN 201080046276A CN 102574807 A CN102574807 A CN 102574807A
Authority
CN
China
Prior art keywords
compound
salt
compounds
mmol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800462763A
Other languages
English (en)
Chinese (zh)
Inventor
C·哈姆杜希
J·P·莱恩斯瓦拉
P·麦提
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102574807(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102574807A publication Critical patent/CN102574807A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800462763A 2009-10-15 2010-10-11 螺哌啶化合物及其用于治疗糖尿病的药用 Pending CN102574807A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US61/251,839 2009-10-15
US30333410P 2010-02-11 2010-02-11
US61/303,334 2010-02-11
PCT/US2010/052126 WO2011046851A1 (en) 2009-10-15 2010-10-11 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes

Publications (1)

Publication Number Publication Date
CN102574807A true CN102574807A (zh) 2012-07-11

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800462763A Pending CN102574807A (zh) 2009-10-15 2010-10-11 螺哌啶化合物及其用于治疗糖尿病的药用

Country Status (25)

Country Link
US (1) US8383642B2 (cg-RX-API-DMAC7.html)
EP (1) EP2488500A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013508279A (cg-RX-API-DMAC7.html)
KR (1) KR20120051777A (cg-RX-API-DMAC7.html)
CN (1) CN102574807A (cg-RX-API-DMAC7.html)
AR (1) AR078522A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010307094A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012008889A2 (cg-RX-API-DMAC7.html)
CA (1) CA2777775A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012000921A1 (cg-RX-API-DMAC7.html)
CO (1) CO6531458A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120177A (cg-RX-API-DMAC7.html)
DO (1) DOP2012000105A (cg-RX-API-DMAC7.html)
EA (1) EA201270560A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011799A (cg-RX-API-DMAC7.html)
IL (1) IL218344A0 (cg-RX-API-DMAC7.html)
MA (1) MA33662B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012004420A (cg-RX-API-DMAC7.html)
NZ (1) NZ598972A (cg-RX-API-DMAC7.html)
PE (1) PE20121437A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012500705A1 (cg-RX-API-DMAC7.html)
TN (1) TN2012000152A1 (cg-RX-API-DMAC7.html)
TW (1) TW201124415A (cg-RX-API-DMAC7.html)
WO (1) WO2011046851A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202560B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120834A1 (es) 2009-03-23 2012-07-25 Glenmark Pharmaceuticals Sa Derivados de furopirimidindiona como moduladores de trpa1
ES2456515T3 (es) 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Derivados de pirimidindiona fusionados como moduladores de TRPA1
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
PH12012501456A1 (en) 2009-12-25 2012-10-29 Mochida Pharm Co Ltd Novel 3-hydroxy -5- arylisothiazole derivative
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
EP2683251B1 (en) 2011-03-11 2021-08-25 Intercontinental Great Brands LLC Method of forming multilayer confectionery
AR085990A1 (es) 2011-04-27 2013-11-13 Mochida Pharm Co Ltd Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
AR087451A1 (es) 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
UY35143A (es) 2012-11-16 2014-05-30 Bristol Myers Squibb Co Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
CN105722841A (zh) * 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
EP3207928B1 (en) * 2014-10-17 2021-03-10 Hyundai Pharm Co., Ltd. Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
DK3737470T5 (da) 2018-01-08 2024-05-27 Celon Pharma Sa 3-phenyl-4-hexynsyrederivater som gpr40-agonister
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1768041A (zh) * 2003-04-04 2006-05-03 麦克公司 作为黑皮质素-4受体激动剂的酰化螺哌啶衍生物
EP1731505A1 (en) * 2004-03-30 2006-12-13 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
CN1901908A (zh) * 2003-11-04 2007-01-24 伊利舍医药品公司 治疗性化合物及其用途
US20090170908A1 (en) * 2007-10-26 2009-07-02 Japan Tobacco Inc. Spiro compounds and pharmaceutical use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2033644A1 (en) 2001-04-18 2009-03-11 Euro-Celtique S.A. Spiroindene and spiroindane compounds
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
EP2224803B1 (en) 2007-11-21 2014-04-02 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1768041A (zh) * 2003-04-04 2006-05-03 麦克公司 作为黑皮质素-4受体激动剂的酰化螺哌啶衍生物
CN1901908A (zh) * 2003-11-04 2007-01-24 伊利舍医药品公司 治疗性化合物及其用途
EP1731505A1 (en) * 2004-03-30 2006-12-13 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
US20090170908A1 (en) * 2007-10-26 2009-07-02 Japan Tobacco Inc. Spiro compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
CR20120177A (es) 2012-06-06
AR078522A1 (es) 2011-11-16
ECSP12011799A (es) 2012-07-31
PE20121437A1 (es) 2012-10-26
CL2012000921A1 (es) 2012-09-14
CA2777775A1 (en) 2011-04-21
NZ598972A (en) 2013-06-28
EA201270560A1 (ru) 2012-09-28
DOP2012000105A (es) 2013-01-31
JP2013508279A (ja) 2013-03-07
EP2488500A1 (en) 2012-08-22
CO6531458A2 (es) 2012-09-28
PH12012500705A1 (en) 2012-10-29
MX2012004420A (es) 2012-05-08
MA33662B1 (fr) 2012-10-01
US20110092531A1 (en) 2011-04-21
WO2011046851A1 (en) 2011-04-21
TW201124415A (en) 2011-07-16
AU2010307094A1 (en) 2012-04-19
KR20120051777A (ko) 2012-05-22
IL218344A0 (en) 2012-04-30
BR112012008889A2 (pt) 2019-09-24
US8383642B2 (en) 2013-02-26
TN2012000152A1 (en) 2013-12-12
ZA201202560B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
US8383642B2 (en) Spiropiperidine compounds
CN102648195B (zh) 新的螺哌啶化合物
KR101570624B1 (ko) 당뇨병의 치료에 유용한 신규 1,2,3,4-테트라히드로퀴놀린 유도체
RU2650506C2 (ru) Агонист рецептора gpr40, способы его получения и фармацевтические композиции, содержащие его в качестве активного ингредиента
KR101157334B1 (ko) Fxr을 조절하기 위한 화합물 및 방법
KR101889695B1 (ko) S1p 조절제로서의 스피로―사이클릭 아민 유도체
WO2015024448A1 (zh) 苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
TW201410655A (zh) 咪唑啉類衍生物、其製備方法及其在醫藥上的應用
CN103224492B (zh) 14-芳基醚穿心莲內酯衍生物及其制备方法和应用
JP2023530709A (ja) 甲状腺様作用剤
RU2722441C2 (ru) Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена
CN118496142B (zh) 芳基烷基胺类化合物及其制备方法和用途
WO2005009104A2 (en) Benzoic and phenyl acetic acid derivatives as hnf-4 modulators
CN108239029B (zh) 一类四氢异喹啉化合物及其盐的制备和医药用途
WO2010060277A1 (zh) 取代乙酰肼类衍生物及其制备方法和用途
WO2005017185A2 (en) HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS
TW202440081A (zh) σ-1受體拮抗劑及其應用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20120711

C20 Patent right or utility model deemed to be abandoned or is abandoned